Currently, there are 239.74M common shares owned by the public and among those 239.44M shares have been available to trade.
The company’s stock has a 5-day price change of -8.89% and -4.93% over the past three months. BNTX shares are trading -1.77% year to date (YTD), with the 12-month market performance up to 14.68% higher. It has a 12-month low price of $76.53 and touched a high of $131.49 over the same period. BNTX has an average intraday trading volume of 837.66K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -2.91%, -1.81%, and 11.66% respectively.
Institutional ownership of BioNTech SE ADR (NASDAQ: BNTX) shares accounts for 19.50% of the company’s 239.74M shares outstanding.
It has a market capitalization of $26.83B and a beta (3y monthly) value of 0.17. The earnings-per-share (ttm) stands at -$2.15. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.70% over the week and 3.47% over the month.
Earnings per share for the fiscal year are expected to decrease by -183.13%, and -4.77% over the next financial year.
Looking at the support for the BNTX, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on January 10, 2025, with the firm’s price target at $172. Wells Fargo coverage for the BioNTech SE ADR (BNTX) stock in a research note released on December 11, 2024 offered a Overweight rating with a price target of $170. BMO Capital Markets was of a view on December 02, 2024 that the stock is Outperform, while Evercore ISI gave the stock Outperform rating on November 19, 2024, issuing a price target of $110- $125. Berenberg on their part issued Buy rating on November 19, 2024.
